Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 16/20 | 0.57 |
| ▸ | CDK1 | P06493 | 3/20 | 0.45 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19370192 | 0.91 | NT5E (0.58) | NT5ECDK1CDK5 | |
| SCHEMBL19370203 | 0.90 | NT5E (0.52) | NT5ECDK1CDK5 | |
| SCHEMBL24078875 | 0.90 | NT5E (0.47) | NT5ECDK1CDK5CDK2 | |
| SCHEMBL21450235 | 0.89 | NT5E (0.54) | NT5ECDK1CDK2 | |
| SCHEMBL19370180 | 0.89 | NT5E (0.58) | NT5ECDK1CDK5CDK2 | |
| SCHEMBL19370237 | 0.89 | NT5E (0.46) | NT5ECDK1CDK5KDM4ENPC1 | |
| SCHEMBL22843632 | 0.88 | NT5E (0.54) | NT5ECDK1CDK5KDM4ENPC1 | |
| SCHEMBL24078883 | 0.88 | NT5E (0.45) | NT5ECDK1CDK5KDM4ENPC1 | |
| SCHEMBL24078902 | 0.88 | NT5E (0.57) | NT5ECDK1CDK5CDK2 | |
| SCHEMBL19370340 | 0.88 | NT5E (0.48) | NT5ECDK1CDK5KDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10239912-B2 | Modulators of 5′-nucleotidase, ecto and the use thereof | ARCUS BIOSCIENCES, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20170267710-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ARCUS BIOSCIENCES, INC. | 2017-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267710-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ENTPD5, NT5C2, NT5E | NT5E 3/4885CDK1 3655/4885CDK5 1450/4885 |
| US-10239912-B2 | Modulators of 5′-nucleotidase, ecto and the use thereof | ENTPD5, NT5C2, NT5E | NT5E 3/4885CDK1 3650/4885CDK5 1552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.